778 reports of this reaction
4.1% of all RAVULIZUMAB reports
#2 most reported adverse reaction
ASTHENIA is the #2 most commonly reported adverse reaction for RAVULIZUMAB, manufactured by Alexion Pharmaceuticals Inc.. There are 778 FDA adverse event reports linking RAVULIZUMAB to ASTHENIA. This represents approximately 4.1% of all 19,021 adverse event reports for this drug.
Patients taking RAVULIZUMAB who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is moderately reported among RAVULIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to asthenia, the following adverse reactions have been reported for RAVULIZUMAB:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 778 FDA reports for RAVULIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 4.1% of all adverse event reports for RAVULIZUMAB, making it one of the most commonly reported side effect.
If you experience asthenia while taking RAVULIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.